2024
F-18 | Comparison of the Safety and Efficacy of Endovascular Interventions for the Treatment of Superficial Femoral Artery Disease: A Network Meta-analysis
Schwartz A, Shah Y, Huang H, Francese D, Shah T, Lansky A. F-18 | Comparison of the Safety and Efficacy of Endovascular Interventions for the Treatment of Superficial Femoral Artery Disease: A Network Meta-analysis. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 101827. DOI: 10.1016/j.jscai.2024.101827.Peer-Reviewed Original Research
2023
Impact of sex on Transcatheter aortic valve replacement outcomes: Results of a single-center study
See C, Wang Y, Yang Y, Tirziu D, Papoutsidakis N, Francese D, Kaple R, Cleman M, Lansky A, Forrest J. Impact of sex on Transcatheter aortic valve replacement outcomes: Results of a single-center study. International Journal Of Cardiology 2023, 398: 131643. PMID: 38065329, DOI: 10.1016/j.ijcard.2023.131643.Peer-Reviewed Original ResearchNew-generation valvesTranscatheter Aortic Valve Replacement OutcomesImpact of sexTAVR outcomesArtery diseaseYale-New Haven HospitalSTS mortality scorePeripheral artery diseaseSingle-center studyCoronary artery diseaseKaplan-Meier curvesLog-rank testNew Haven HospitalSex-based disparitiesSignificant differencesCardiovascular comorbiditiesSAPIEN 3Transfemoral accessSAPIEN XTConsecutive patientsCox modelingMortality scoreEvolut RFemale sexEvolut PROImpact of New‐Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single‐Center Study
See C, Wang Y, Huang H, Parise H, Yang Y, Tirziu D, Francese D, Papoutsidakis N, Bader E, Kaple R, Cleman M, Lansky A, Forrest J. Impact of New‐Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single‐Center Study. Journal Of Interventional Cardiology 2023, 2023: 5390338. PMID: 37292113, PMCID: PMC10247319, DOI: 10.1155/2023/5390338.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementNew-onset conduction disturbancesAortic valve replacementPersistent conduction disturbancesConduction disturbancesValve replacementSurgical aortic valve replacementSingle-center retrospective analysisYale-New Haven HospitalSingle-center studyCause mortality ratesCause mortality riskLong-term outcomesNew Haven HospitalPeriprocedural factorsAortic stenosisConsecutive patientsTAVR proceduresTerm outcomesRetrospective analysisMortality riskMortality ratePatientsOutcomesPatient's ECG
2016
Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials
Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. The American Journal Of Cardiology 2016, 118: 6-16. PMID: 27181566, DOI: 10.1016/j.amjcard.2016.04.005.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa inhibitorsPercutaneous coronary interventionMajor adverse cardiac eventsEfficacy of bivalirudinAdverse cardiac eventsDiabetes mellitusMajor bleedingCoronary interventionBivalirudin treatmentCause mortalityCardiac eventsNon-coronary artery bypass graft-related major bleedingPrimary efficacy end pointPrimary safety end pointUrgent Intervention Triage StrategyAcute Myocardial Infarction trialIIb/IIIa inhibitorsEnd pointHORIZONS-AMI trialPCI Linking AngiomaxComposite of deathEfficacy end pointMyocardial Infarction trialSafety end pointPatient-level data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply